Nanobac Pharmaceuticals IncOver The Counter Market:NNBP
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close--- / 0.0000
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Nanobac Pharmaceuticals Inc | 250.0 | 0.0x | --- |
BioSyntech Inc | 1.2K | 0.0x | --- |
Bioasis Technologies Inc | 7.9K | 0.0x | --- |
Stromacel Inc | 10.0 | 0.0x | --- |
MetaStat Inc | 590.0 | 0.0x | --- |
HempAmericana Inc | 2.9K | --- | --- |
Company Information
Nanobac Pharmaceuticals, Incorporated (Nanobac) is a research-based, bio-lifescience company. The Company is primarily engaged in the discovery and development of products and services to improve people’s health through the detection and treatment of Calcifying Nanoparticles (CNPs), otherwise known as nanobacteria. Its research is directed toward establishing the pathogenic role of nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease. Nanobac’s drug discovery and development is focused on new and existing compounds that inhibit, destroy or neutralize CNPs. Nanobac manufactures and markets In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products (blood and tissue tests) include assays, antibodies and reagents for recognizing CNPs.
Contact Information
- Headquarters
- 5025 W Lemon StTAMPA, FL, United States 33609-1101
- Phone
- 813-377-4434
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer, Chief Financial Officer
- John Stanton
- Director
- Alexander Edwards
- Director
- Benedict Maniscalco
- Director
- Stephen Rechtschaffen
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $250.00 |
|---|---|
Revenue (TTM) | $18.0K |
Shares Outstanding | 249.5M |
Nanobac Pharmaceuticals Inc does not pay a dividend. | |
Beta | 0.53 |
EPS | $-0.03 |
Book Value | $-0.01 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 0.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -35,966.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
